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ORIGINAL ARTICLE
Congenital adrenal hyperplasia (CAH) is a disor-
der of adrenal steroid biosynthesis with autosomal
recessive inheritance.1,2 21-Hydroxylase deficiency
(21-OHD) accounts for > 90% of classic cases of
CAH and is characterized by cortisol deficiency
and androgen excess, with or without aldosterone
deficiency. Classic CAH caused by 21-OHD has a
wide spectrum of clinical variations, including
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Background/Purpose: Data about the clinical manifestations of congenital adrenal hyperplasia caused 
by 21-hydroxylase deficiency (21-OHD) are lacking in Taiwan. Therefore, this study analyzed the clinical
features of 21-OHD in Taiwanese children to improve the diagnosis of this disorder, and to provide 
background information regarding the ongoing neonatal screening program for 21-OHD in Taiwan.
Methods: Eighty children with 21-OHD, 39 with the salt-wasting (SW) type and 41 with the simple-
virilizing (SV) type, were evaluated by a review of their medical records. Their clinical symptoms and signs,
laboratory findings, and genetic mutations were analyzed.
Results: The most frequent features in 21-OHD patients were hyperpigmentation and signs of androgen
excess. Clinical manifestations related to hyponatremia such as poor feeding, poor weight gain, and dehy-
dration were noted most frequently in patients with SW-type 21-OHD. Five patients had low serum cortisol
with elevated plasma adrenocorticotropic hormone levels, and 22 patients had elevated dehydroepiandros-
terone sulfate levels. All had elevated blood levels of 17-hydroxyprogesterone, androstenedione and
testosterone. Hyponatremia and hyperkalemia were detected in 29 patients with SW-type 21-OHD. In
terms of molecular diagnosis, mutations at IVS2-12A/C G and gene deletion were the most frequent muta-
tions detected in SW-type 21-OHD, while I172N and mutation at IVS2-12A/C  G were most frequent in 
SV type.
Conclusion: Taiwanese children with 21-OHD have characteristic clinical findings such as hyperpigmen-
tation, androgen excess, and failure to thrive. There is a good correlation between genotype and pheno-
type. Laboratory tests, including serum 17-hydroxyprogesterone, androstenedione, and testosterone levels
are more sensitive than serum cortisol or dehydroepiandrosterone sulfate levels for diagnosing 21-OHD in
prepubertal children. [J Formos Med Assoc 2010;109(2):148–155]
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salt-wasting (SW) and simple-virilizing (SV) types,
which are associated with the severity of impaired
21-hydroxylase activity.
The gene that encodes 21-hydroxylase,
CYP21A2, is known to be located at the HLA
class III region of the short arm of chromosome
6 (6p21.3).3 Most mutations that involve the
CYP21A2 are either large gene deletions4,5 or trans-
fer of deleterious sequences from the pseudo-
gene CYP21A1P to the active gene CYP21A2, in a
process termed gene conversion.6–9
The diagnosis of 21-OHD is based on the
clinical presentation and laboratory tests, includ-
ing the adrenocorticotropin (ACTH) stimulation
test.10,11 A newborn screening program has been
implemented in Taiwan since 2007 to prevent
morbidity and mortality, by testing blood spot 
17-hydroxyprogesterone (17-OHP) levels.12,13
However, false-negative neonatal screening results
in severely affected patients with 21-OHD are still
observed.14
This study analyzed the initial clinical and lab-
oratory features of Taiwanese children with 21-
OHD in the pre-screening era, to arouse physicians’
index of suspicion for diagnosing this disorder. It
also aimed to provide background information
for the ongoing neonatal screening program for
21-OHD in Taiwan.
Patients and Methods
Subjects
Eighty patients diagnosed with classic CAH
caused by 21-OHD, from 1977 to 2006, but not
detected by neonatal screening at the Depart-
ment of Pediatrics, National Taiwan University
Hospital were enrolled. Their medical records
were reviewed throughly. The diagnosis of 
21-OHD was based on clinical evidence of an-
drogen excess, glucocorticoid and/or mineralo-
corticoid deficiency, with elevated basal and/or
ACTH-stimulated 17-OHP levels. Patients with
serum sodium levels < 135 mmol/L and/or serum
potassium levels > 5.5 mmol/L were classified as
SW-type 21-OHD.
Complete physical examination and assess-
ment of external genitalia were carried out in 
all patients with 21-OHD upon diagnosis. Lab-
oratory tests, including serum levels of sodium,
potassium, chloride, basal ACTH, cortisol, 17-
OHP, dehydroepiandrosterone sulfate (DHEAS),
androstenedione, and testosterone, as well as
blood gas analysis were also checked upon diag-
nosis. All of the blood samples were obtained
before the initiation of hormone replacement
therapy. The 60-minute ACTH stimulation test was
performed in 22 patients to confirm the diagnosis
of 21-OHD as previously reported.11 All serum
hormone levels were assayed by commercially
available kits.
Bone age was determined in patients aged > 3
years and was evaluated according to Greulich
and Pyle’s criteria.15 Karyotyping and pelvic so-
nography were performed in girls who presented
with ambiguous genitalia.
Molecular analysis
After diagnosis of 21-OHD, 62 patients (includ-
ing 11 siblings from 5 families) underwent geno-
typing of the CYP21A2 gene in peripheral blood
leukocytes. Both parents were also genotyped to
confirm the origin of the mutations. All of the sub-
jects provided informed consent. The eight most
common mutation sites from exons 1 to 8 were
analyzed initially by allele-specific polymerase
chain reaction (PCR), as described previously.16
When none of the eight point mutations or
deletions could account for a diseased allele, direct
single strand conformation polymorphism (SSCP)
analysis was done. Primary PCR was performed to
amplify specifically the full-length of CYP21A2,
as previously described.17 Ten sets of primers were
designed to perform secondary PCR using the
primary PCR products as templates to amplify 
10 exons. The secondary PCR products were sub-
jected to SSCP analysis using a GenePhor Unit
(Pharmacia Biotech, Uppsala, Sweden). The un-
characterized band of exon 9 on the SSCP gel was
cut and the DNA was extracted and re-amplified
with the same SSCP primers. An automated 
sequencer (ABI PRISM 377 Genetic Analyzer;
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Applied Biosystems, Foster City, CA, USA) di-
rectly sequenced the PCR products.
Statistical analysis
Data were expressed as median and range, and
analyzed using SPSS version 15.0 (SPSS Inc.,
Chicago, IL, USA). The Mann-Whitney U test was
used for between-group comparison. A p value
< 0.05 was considered statistically significant.
Results
Demographic data
Of the 80 21-OHD patients, 11 were siblings from
five families. None of the 80 patients had a family
history of consanguinity. Thirty-nine (21 boys and
18 girls) patients had SW-type and 41 (10 boys and
31 girls) had SV-type 21-OHD. As shown in Table 1,
boys with SW-type 21-OHD detected by the par-
ents was significantly younger than those with SV-
type (8 days vs. 4.5 years; p < 0.01). The situation
was similar for girls. However, boys were detected
at a later age than girls for both SW- and SV-type
21-OHD. The median age of diagnosis for SW-
type 21-OHD was also significantly younger than
that for SV-type (p < 0.01). However, the median
age of diagnosis did not differ significantly be-
tween boys and girls for either SW- or SV-type 
21-OHD.
Clinical manifestations
The clinical manifestations of 21-OHD patients are
shown in Table 2. The most frequent initial clinical
Table 1. Age at detection and diagnosis of children with 21-hydroxylase deficiency*
Salt wasting type Simple virilizing type
Male Female p Male Female p
Age at detection 8 d 1 d < 0.01 4.5 yr 1 d < 0.01
(1 d–5.8 yr) (1–10 d) (3.4–11.9 yr) (1 d–14.4 yr)
Age at diagnosis 27 d 22 d 0.49 5.4 yr 5.3 yr 0.62
(10 d–5.8 yr) (5–68 d) (3.4–12 yr) (3 d–15.3 yr)
*Data presented as median (range).
Table 2. Clinical manifestations of patients with 21-hydroxylase deficiency*
Salt wasting type (n = 39) Simple virilizing type (n = 41)
Male (n = 21) Female (n = 18) Male (n = 10) Female (n = 31)
p
GI upset 13/17 (76) 10/13 (77) – – 0.98
Poor feeding 19/20 (95) 13/16 (81) – – 0.19
Poor weight gain 18/20 (90) 13/16 (81) – – 0.45
Dehydration 16/16 (100) 11/13 (85) – – 0.10
Hyperpigmentation 10/13 (77) 10/13 (77) 6/9 (67) 12/26 (46) 0.29
Clitoromegaly – 18/18 (100) – 28/28 (100) –
Ambiguous genitalia – 15/18 (83) – 18/31 (58) –
Enlarged penis – – 6/10 (60) – –
Development of pubic hair – – 6/10 (60) 12/31 (39) 0.24
Deepening of voice – – 3/10 (30) – –
Acne – – 5/10 (50) 9/30 (30) 0.25
Rapid growth – – 10/10 (100) 21/31 (68) 0.04
Tall stature – – 10/10 (100) 10/31 (32) < 0.01
Advanced bone age – – 10/10 (100) 16/22 (73) 0.07
*Data presented as the number of patients with symptoms and signs/the number of patients with symptoms and signs recorded (%).
GI = gastrointestinal.
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manifestations in boys with SW-type 21-OHD were
dehydration, poor feeding, and failure to thrive, and
the most frequent initial clinical manifestations in
girls with SW-type were clitoromegaly, dehydra-
tion, and ambiguous genitalia. Conversely, the
most frequent clinical manifestations of boys with
SV-type 21-OHD were rapid growth, tall stature,
and advanced bone age, whereas the most frequent
initial clinical manifestations in girls with SV-
type were clitoromegaly and advanced bone age.
Laboratory findings
As shown in Table 3, basal ACTH and cortisol lev-
els were determined in 21 and 29 patients with 21-
OHD, respectively. The median basal ACTH level
was 34.5 pmol/L (range, 5.5–275.0 pmol/L) and
the median basal cortisol level was 199.0 nmol/L
(range, 85.6–461.0 nmol/L). Only five of the 21
patients had elevated ACTH levels with low corti-
sol levels, and nine had elevated ACTH level with
normal cortisol levels. The median basal serum
17-OHP level in 38 patients was 384.0 nmol/L
(range, 13.8–11,005.0 nmol/L). All of these val-
ues were above the normal control basal serum
17-OHP levels.
Serum DHEAS and androstenedione levels
were measured in 28 and 29 patients, respec-
tively. The median value was 4.9 μmol/L (range,
0.8–66.5 μmol/L) for DHEAS and 43.9 nmol/L
(range, 19.9–2820 nmol/L) for androstenedione.
Twenty-two patients had elevated serum DHEAS
levels, and all had serum androstenedione levels
above the normal range as suggested by Tung 
et al.18 Serum testosterone was measured in 
47 patients. The median value was 14.6 nmol/L
(range, 1.7–293.0 nmol/L). All of these values
were above the normal range for the age group
concerned. There were statistically significant
differences between SW- and SV-type 21-OHD
for serum androstenedione and testosterone 
levels (Table 3).
Serum electrolyte levels were measured in 32
patients with SW-type 21-OHD. Thirty-one had
hyponatremia and 29 had hyperkalemia at the
time of diagnosis, and four had seizures caused
by hyponatremia. Among patients with SW-type
21-OHD, 14/16 (88%) boys had a serum so-
dium level below 125 nmol/L, and 8/16 (50%)
girls had a serum sodium level below 125 nmol/
L (p < 0.05). Seventeen patients with SW-type 
Table 3. Laboratory findings on diagnosis of 21-hydroxylase deficiency*
Total Salt wasting type Simple virilizing type
Hormone
n Serum levels n Serum levels n Serum levels
p Normal range
ACTH (pmol/L) 21 34.5 (5.5–275.0) 3 45.3 (38.5–268.0) 18 23.7 (5.5–275.0) NS 2.2–14.3
Cortisol (nmol/L) 29 199 (85.6–461.0) 5 205 (141–301) 24 197 (85.6–461.0) NS 138–690
17-OHP (nmol/L) 38 384 (13.8–11,005.0) 11 802 (22.8–11,005.0) 27 377 (13.8–1253.0) NS < 10
DHEAS (μmol/L) 28 4.9 (0.8–66.5) 8 6.2 (0.8–66.5) 20 4.0 (1.1–23.7) NS –†
Androstenedione 29 43.9 (19.9–2820.0) 9 484.0 (28.1–2820.0) 20 33.4 (19.9–100.0) < 0.01 –†
(nmol/L)
Testosterone 47 14.6 (1.7–293.0) 17 28.7 (7.9–293.0) 30 9.8 (1.7–52.7) < 0.01 < 0.7
(nmol/L)
Na (mmol/L) – 32 121 (90–138) – – 135–145
K (mmol/L) – 32 7.6 (4.0–10.6) – – 3.5–5.5
Cl (mmol/L) – 25 91 (66–107) – – –
Bicarbonate – 17 10.4 (3.4–15.2) – – –
(mmol/L)
*Data presented as median (range) or range; †see reference 18 for age-dependent normal range. ACTH = adrenocorticotropin; NS = not significant; 17-
OHP = 17-hydroxyprogesterone; DHEAS = dehydroepiandrosterone sulfate; Na = sodium ion; K = potassium ion; Cl = chloride ion.
21-OHD underwent blood gas analysis at the
time of diagnosis. The median serum bicarbonate
level was 10.4 mmol/L (range, 3.4–15.2 mmol/L)
(Table 3).
Molecular diagnosis
The results of molecular analysis of 57 patients
from different families are shown in Table 4.
Overall, mutations were detected in 94% of the
chromosomes examined. The most frequent mu-
tations detected were I172N (22.8%), mutation 
at IVS2-12A/CG (21.1%), and gene deletion
(14%). Among these, IVS2-12A/CG (24.1%)
and gene deletion (24.1%) were detected most
frequently in patients with SW-type 21-OHD,
whereas Il72N (46.4%) and IVS2-12A/CG
(17.9%) were detected most frequently in patients
with SV-type 21-OHD. One novel mutation at
exon 9 was identified in a patient with SV-type
21-OHD. This involved a deletion from codons
396 to 400 of exon 9, with a segment from intron
6 (nucleotides 1520–1560) inserted at codon 396.
This mutation caused a stop codon at 15 codons
downstream from the insertion site.
Among the 50 patients with mutations de-
tected on both chromosomes, four each were 
homozygotes for gene deletion, large gene con-
version, or IVS2-12A/CG. All four patients had
SW-type 21-OHD. Three homozygotes that car-
ried the mutation Il72N had SV-type 21-OHD.
One patient with compound heterozygosity for
IVS2-12A/CG in trans with R356W was SV-
type. Twenty-four patients who were compound
heterozygotes with any combination of gene de-
letion, large gene conversion, IVS2-12A/CG,
c.707-714del, a cluster of mutations at exon 6,
stop mutation, or R356W had SW-type 21-OHD.
On the other hand, 18 patients who were com-
pound heterozygotes for I172N mutations in
trans with any of the above-mentioned muta-
tions had SV-type 21-OHD.
Discussion
CAH is a group of autosomal recessive disorders
that are caused most frequently by 21-OHD.2,19,20
Classic CAH caused by 21-OHD can be further
divided into SW- and SV-types according to the
severity of impaired 21-hydroxylase activity. In
the present study, the number of SW- and SV-type
patients was similar. The proportion of SW-type
patients in our study was less than that expected
based on previous studies21–24 or our newborn
screening program.13 Such discrepancy suggests
that a greater proportion of SW-type 21-OHD pa-
tients in the pre-screening era could have died
from adrenal crisis without a definite diagnosis,
because of the nonspecific presentation in boys
with SW-type 21-OHD or their parents’ and doc-
tors’ lack of knowledge of this disorder. Excess
androgen production affects the external geni-
talia of girls with CAH, therefore, the clinical
manifestations in girls are more obvious than
those in boys with CAH. The age at diagnosis
was not significantly different between boys and
girls in the present study, which is different from
previous reports.21,22,24 It also reflects a lack of
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Table 4. Allele distribution in patients with 21-
hydroxylase deficiency (n = 57)
Mutational allele
Number of 
chromosomes*
P30L 1 (0.9)
In2 24 (21.1)
P30L, In2, Ex3 8 (7.0)
In2, Ex3 6 (5.3)
I172N 26 (22.8)
P30L, In2, Ex3, I172N 1 (0.9)
Ex6 cluster 1 (0.9)
Q318X 5 (4.4)
R356W 10 (8.8)
Q318X, R356W 4 (3.5)
cdn483 GGC 3 (2.6)
R483P 1 (0.9)
Ex9,insdels 1 (0.9)
Deletion 16 (14.0)
Unknown 7 (6.1)
Total 114 (100)
*Numbers in parentheses denote the percentage of chromosomes.
P30L = Pro30Leu; In2 = IVS2-12 A/CG; Ex3 = c.707-714del;
I172N = Ile172Asn; Ex6 = cluster of three mutations in exon 6;
Q318X = Gln318term; R356W = Arg356Trp.
alertness of parents and doctors in diagnosing
CAH in the pre-screening era in Taiwan, even with
obvious findings on the external genitalia of girls
with CAH.
Although CAH caused by 21-OHD impairs
glucocorticoid synthesis, most of the patients in
our study had low, normal basal serum cortisol
levels upon diagnosis. However, such levels are
not adequate for patients in the presence of
stress and elevated ACTH levels. Conversely,
serum basal 17-OHP levels were elevated in all of
these patients. These results demonstrated that
serum 17-OHP levels are more reliable than
plasma ACTH or cortisol levels for diagnosing
21-OHD in children.
In terms of serum androgen levels, 79% of
patients had serum DHEAS above the normal
range for their age, whereas all patients had serum
androstenedione and testosterone levels above
the normal range for their age. There was no
statistically significant difference in serum DHEAS
levels in patients with SW- and SV-type 21-OHD.
However, the serum levels of androstenedione
and testosterone in SW-type patients were signif-
icantly higher than those of SV-type patients (p <
0.01). Although serum DHEAS level is specific
for adrenal androgen production, the data here
showed that serum androstenedione and testos-
terone levels are more sensitive in diagnosing 
21-OHD than is serum DHEAS level, which con-
firms our previous findings.25
In this study, the distinction between SW- and
SV-type 21-OHD was based on serum electrolyte
levels. It is well known that plasma renin activity
and aldosterone levels are more precise in re-
flecting the activity of the renin-angiotensin-
aldosterone system, and patients with SW-type
21-OHD have high renin activity and low plasma
aldosterone levels.26 A large proportion of the pa-
tients in the present study were diagnosed before
the availability of assays, therefore, such data were
not presented in this study. However, the determi-
nation of plasma renin activity or direct renin level
is recommended for the diagnosis of CAH.27
The most frequent mutations in our patients
were I172N, IVS2-12A/CG and gene deletion,
which were similar to those previously re-
ported.17,28 Among these, IVS2-12A/CG and
gene deletion were the most common mutations
in SW-type 21-OHD, and I172N and IVS2-12A/
CG were the most common in SV-type. It has
been reported previously that the most frequent
mutations are deletion and large gene conver-
sion in SW-type 21-OHD, IVS2-12A/CG in 
SW- and SV-types, and I172N in SV-type.19,20
The effect of CYP21A2 mutations on the enzy-
matic activity of 21-hydroxylase is well docu-
mented.4,6–8,19,20,29 The results here confirmed
the correlation between specific mutations and
phenotypes reported previously.19,20
All patients with homozygous mutations for
CYP21A2 reflected the severity of impaired 21-
hydroxylase activity. The phenotype of our pa-
tients with compound heterozygosity for two
different CYP21A2 mutations was often compati-
ble with that of the less severe gene defects.19,20,30
Furthermore, most of our patients who were het-
erozygous for IVS2-12A/CG with a more se-
vere gene defect had SW-type 21-OHD, but a
minority of patients with this mutation had SV-
type. The possibility that intronic mutations such
as IVS2-12A/CG alternatively activate cryptic
splice acceptor sites, with the production of some
normally processed mRNA, could explain why
patients with SV-type 21-OHD carry IVS2-12A/
CG.6,19,20,29,30 On the other hand, one patient
who was a compound heterozygote for P30L and
large gene conversion (P30L, IVS2-12A/CG,
c.707-714del, I172N) had SV-type 21-OHD. Al-
though the P30L enzyme activity has been re-
ported to be impaired mildly in vitro, the SV
clinical phenotype has been reported in patients
who are compound heterozygotes for P30L and
a severe mutation.31,32 The P30L mutation as part
of a larger gene deletion/conversion event with a
junction site before intron 2 has been proposed
to account for such a finding.32
In conclusion, the present study demonstrates
the clinical findings of Taiwanese children with
CAH caused by 21-OHD, as well as a good correla-
tion between genotype and phenotype in these pa-
tients. Although clinical findings are more obvious
21-OHD in Taiwanese children
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in girls, the diagnosis of 21-OHD is delayed in both
boys and girls. This study could help physicians to
recognize this disease entity. With improved knowl-
edge of parents and physicians, and with the help
of the neonatal screening program for 21-OHD,
such a delay in diagnosis can hopefully be avoided
in Taiwan in the near future.
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